• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845

3-Bromo-7-Methoxyisoquinoline: A Comprehensive Overview

3-Bromo-7-Methoxyisoquinoline is a fascinating compound with the CAS number 1246554-40-4, belonging to the class of isoquinoline derivatives. These compounds are known for their unique structural features and diverse biological activities, making them a subject of intense research in the fields of pharmacology, organic chemistry, and medicinal chemistry. The isoquinoline core, a bicyclic structure consisting of a benzene ring fused with a pyridine ring, serves as a versatile scaffold for the introduction of various substituents, which can significantly influence the compound's properties and applications.

The 3-bromo-7-methoxyisoquinoline structure is characterized by the presence of a bromine atom at position 3 and a methoxy group at position 7 on the isoquinoline backbone. This substitution pattern not only enhances the compound's stability but also imparts unique electronic and steric properties. Recent studies have highlighted the potential of such substituted isoquinolines in drug discovery, particularly in the development of anticancer agents. For instance, researchers have demonstrated that 3-bromo-7-methoxyisoquinoline exhibits significant cytotoxic activity against various cancer cell lines, suggesting its role as a lead compound in antitumor drug design.

One of the most intriguing aspects of 3-bromo-7-methoxyisoquinoline is its ability to modulate cellular signaling pathways. Emerging evidence from biochemical studies indicates that this compound can inhibit key enzymes involved in inflammation and oxidative stress, making it a promising candidate for anti-inflammatory and antioxidant therapies. Furthermore, its ability to interact with specific receptors and ion channels has opened new avenues for exploring its potential in neurodegenerative diseases and cardiovascular disorders.

The synthesis of 3-bromo-7-methoxyisoquinoline typically involves multi-step organic reactions, including Friedlander annulation, nucleophilic substitution, and oxidation processes. Recent advancements in catalytic methods have enabled more efficient and environmentally friendly routes to this compound, reducing production costs and minimizing waste generation. These synthetic strategies are not only pivotal for scaling up production but also pave the way for further structural modifications to optimize pharmacokinetic properties.

In terms of applications, 3-bromo-7-methoxyisoquinoline has shown remarkable potential in preclinical studies as an anticancer agent. Its ability to induce apoptosis in cancer cells while sparing normal cells highlights its selectivity and therapeutic index. Additionally, studies have revealed its role as an inhibitor of histone deacetylases (HDACs), which are critical targets in epigenetic therapy for cancer treatment. This dual functionality underscores the compound's versatility and positions it as a valuable tool in precision medicine.

Another area where 3-bromo-7-methoxyisoquinoline has garnered significant attention is its role in antibacterial research. With the increasing threat of antibiotic resistance, there is an urgent need for novel antimicrobial agents. Recent findings indicate that this compound exhibits potent activity against multidrug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). Its mechanism of action involves disrupting bacterial cell membranes and inhibiting essential metabolic pathways, making it a compelling candidate for next-generation antibiotics.

The pharmacokinetic profile of 3-bromo-7-methoxyisoquinoline is another critical aspect that has been extensively studied. Research has shown that this compound demonstrates moderate solubility and permeability, which are essential for effective drug delivery. However, challenges remain in improving its bioavailability through structural modifications or formulation strategies such as nanoparticle encapsulation or prodrug design.

In conclusion, 3-bromo-7-methoxyisoquinoline represents a compelling example of how structural modifications can enhance the therapeutic potential of isoquinoline derivatives. With its diverse biological activities and promising preclinical results, this compound holds great promise in various therapeutic areas, including oncology, inflammation management, neuroprotection, and antimicrobial therapy. As research continues to unravel its mechanisms of action and optimize its pharmacokinetic properties, 3-bromo-7-methoxyisoquinoline is poised to make significant contributions to the development of innovative medicines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)